Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evaxion Biotech ( (EVAX) ) has shared an announcement.
Evaxion Biotech has announced an extraordinary general meeting to be held on January 17, 2025, where significant proposals, including the reduction of share capital and nominal value of shares, will be discussed. The move aims to address financial losses, and the adjustments will also affect issued warrants, indicating a strategic shift that may impact stakeholders and potentially strengthen the company’s financial position.
More about Evaxion Biotech
Evaxion Biotech is a biotechnology company specializing in the development of AI-driven immunotherapy solutions. Their primary focus is on leveraging artificial intelligence to discover and develop new immunotherapies for the treatment of cancer and infectious diseases.
YTD Price Performance: -86.97%
Average Trading Volume: 50,653
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.99M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.
